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ABSTRACT
Background: Although metabolic syndrome is associated with cardiovascular disease and stroke,
limited information is available on specific brain damage in patients with this syndrome. We inves-
tigated the relationship of the syndrome with white matter (WM) alteration using a voxel-based
approach with diffusion tensor imaging (DTI).
Methods: We compared fractional anisotropy (FA) and apparent diffusion coefficient (ADC) mea-
surements of DTI in 19 patients with metabolic syndrome aged between 50 and 80 years and 19
age-matched controls without any vascular risk factors for the syndrome.
Results: Patients with metabolic syndrome showed an anterior–posterior pattern of deterioration
in WM with reduced FA and increased ADC values compared with controls. WM changes were not
related to any isolated vascular risk factor.
Conclusion: Although the mechanism of this damage is not clear, the results indicate microstruc-
tural white matter alterations in patients with metabolic syndrome, mainly involving the frontal
lobe. Neurology® 2009;73:438 –444
GLOSSARY
ADC  apparent diffusion coefficient; ADC Cont  ADC mean values in the control group; ADC SdMet  ADC mean values in
the patient group; ant  anterior; c  corpus; corr  corrected; DICOM  Digital Imaging and Communications in Medicine;
DTI  diffusion tensor imaging; F  frontal lobe; FA  fractional anisotropy; FA Cont  FA mean values in the control group;
FA SdMet  FA mean values in the patient group; fas  fasciculus; FOV  field of view; FWHM  full-width at half-maximum;
HDL  high-density lipoprotein; inf  inferior; Lb  limbic lobe; MNI  Montreal Neurological Institute; NCEP  National
Cholesterol Education Program; SPM  Statistical Parametric Mapping; Sub  sublobar; sup  superior; T  temporal lobe;
TE  echo time; TI  inversion time; TR  repetition time; WM  white matter.
Metabolic syndrome is a cluster of vascular risk factors defined by the National Cholesterol
Education Program (NCEP) as the presence of at least 3 of the following vascular risk factors:
hypertension, hyperglycemia, hypertriglyceridemia, low levels of high-density lipoprotein
(HDL) cholesterol, and central obesity as measured by waist circumference.1 The worldwide
prevalence of the syndrome is rising: in the United States, 43.5% of the population aged
60–69 years are affected,2 whereas in Europe, approximately one quarter of the adult popula-
tion have the syndrome, the prevalence depending on the specific characteristics of the popula-
tion (age, geographical location, the criteria used to define the syndrome).3
Until now, metabolic syndrome has been associate with a higher risk of stroke,4,5 the pres-
ence of silent lacunar infarcts,6 intracranial arteriosclerosis,7 periventricular hyperintensities,
and subcortical white matter (WM) lesions,8 although to date there is little evidence regarding
the association of brain damage.9,10
Diffusion tensor imaging (DTI) is a technique that provides information on subtle WM changes
associated with aging11 and with cerebrovascular disease12,13 by detecting microstructural alterations.
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The variables most often analyzed by DTI are
fractional anisotropy (FA) and the apparent dif-
fusion coefficient (ADC). FA is a measure of
tract directionality and integrity, whereas ADC
is a measure of water diffusivity.14
We hypothesized that metabolic syn-
drome, as a cluster of vascular risk factors,
would be associated with a subtle pattern of
WM deterioration. To test this possibility, we
performed a comparative study between pa-
tients with metabolic syndrome and healthy
controls without vascular risk factors, using
the DTI approach.
METHODS Subjects. The study included 19 subjects who
fulfilled the criteria for metabolic syndrome as described by the
NCEP,1 along with 19 healthy controls from 2 public medical
centers of Barcelona province (Centres d’atenció primaria) in
Cerdanyola del Vallés and Sant Just Desvern, Barcelona (Spain).
Metabolic syndrome diagnosis requires as a minimum the pres-
ence of 3 of the 5 possible risk factors (table e-1 on the Neurology
Web site at www.neurology.org). Subjects in the patient group ful-
filled 3, 4, or 5 of the diagnostic criteria.
The criterion for selecting healthy control subjects was the
absence of any vascular risk factor included in the criteria for
metabolic syndrome.
All the participants were volunteers, right handed, and aged
between 50 and 80 years. The exclusion criteria were uncor-
rected visual or auditory deficits, alcoholism (more than 28 stan-
dard drink units per week for men and more than 17 standard
drink units per week for womene1 or other drug abuse, a history
of developmental disorders, and current neurologic, hemato-
logic, hormonal, or nutritional disorders and neoplasm. We also
excluded subjects with a history of cardiovascular disease or a
history of acute stroke or TIAs. None of the participants pre-
sented neurologic symptoms according to the Modified Rankin
Scale scores  0.e2
All selected participants completed a screening interview to
check the medical information from their records. A modified
structured clinical interview based on the Structured Clinical
Interview for DSM-IV Axis I disorderse3 was administered to
exclude major psychiatric diseases.
We obtained measures of glucose, HDL cholesterol, and
triglycerides for all participants from blood tests performed in
the reference laboratory of each public medical center. Blood
pressure measures and participants’ waist circumference were re-
corded during the screening sessions.
All subjects had normal general cognitive performance ac-
cording to the Mini-Mental State Examinatione4 (scores 26).
Global IQ was estimated by the Vocabulary subtest of the Wechsler
Adult Intelligence Scale, 3rd edition.e5 All participants underwent
comprehensive neuropsychological assessmente4 (table e-2).
The study was approved by the ethics committee of the Uni-
versity of Barcelona.
All enrolled subjects signed an informed consent form before
taking part in the study.
MRI data acquisition. DTI sequences were obtained on a
3-T Siemens Magnetom Trio scanner (Erlangen, Germany) be-
longing to the Institut d’ Investigacions Biomédiques August Pi i
Sunyer at the Radiology Service of the Hospital Clinic of Barce-
lona. The DTI sequences were acquired with the following
parameters: repetition time (TR)  5,533 msec, echo time
(TE)  88 msec, acquisition matrix  122  122, field of view
(FOV)  250  250 mm2, diffusion directions  30, slice
thickness  2 mm, gap distance  0.6 mm, number of slices 
44, b values: 0 and 1,000 s/mm2, IPAT factor  2, total scan
time 3:10 minutes. The magnetic resonance protocol included
T1-weighted images to be used for anatomic reference. T1-
weighted images were acquired using a sagittal 3-dimensional
isotropic magnetization-prepared rapid gradient echo sequence:
TR  2,300 msec, TE  2.98 msec, inversion time (TI)  900
msec, flip angle  9°, FOV  256  256 mm2, acquisition
matrix  256  256, slice thickness  1 mm, IPAT factor  2,
total acquisition time  748.
Image preprocessing. All image processing was performed
using SPM5 (Statistical Parametric Mapping, Wellcome Depart-
ment of Imaging, Institute of Neurology, University College
London, UK) running in Matlab 7.6 (MathWorks, Natick,
MA). The DTI protocol was administered as follows. FA maps
and ADC maps were obtained from Digital Imaging and Com-
munications in Medicine (DICOM) DTI sequences. B0 image
and FA and ADC maps were reoriented according to the anterior–
posterior commissure line using the same parameters. The
coregister parameters of B0 values were applied to T1. These
parameters were applied to FA and ADC maps to coregister
these maps to the structural image. In this step, we observed a
small mismatch in some areas due to a subtle geometric B0 im-
age distortion produced by eddy currents. We therefore decided
to create a FA template and to normalize FA maps to it to obtain
a better matching between normalized FA maps.e6 For this pur-
pose, high-resolution T1 images were segmented to obtain WM
in native space. WM partitions in native space were normalized
to WM SPM prior maps to ensure good WM normalization.e7
Normalization parameters were then applied to FA maps. Nor-
malized FA maps were averaged and smoothed with a 6-mm
full-width at half-maximum (FWHM) gaussian kernel to create
a customized template of FA images of our sample. In the second
step, each individual FA map was normalized to this FA tem-
plate. The same normalization parameters were applied to ADC
maps. A physics PhD (C.F.), an expert in neuroimage analysis,
carefully inspected the result of the second normalization to en-
sure its accuracy. An 8-mm FWHM gaussian kernel was used to
smooth final ADC and FA images.
Statistical procedure. Two binarized brain masks were used
as an explicit mask in the FA and ADC analyses. In the FA
analysis, we used a mask obtained by thresholding the FA tem-
plate (threshold value  0.5), and in the ADC analysis, we used
the “a priori” SPM5 template (threshold value  0.3). The pro-
cessed FA and ADC images were analyzed using the t test group
comparison in SPM5. Specifically, the contrasts were patients 
controls for FA, and patients  controls for ADC. The reverse
contrasts were also performed. For the FA and ADC contrasts
between groups, we set the threshold at an uncorrected voxel p
value of 0.005, because we only expected subtle WM changes
in our patients, who were normal individuals with vascular risk
factors. However, for statistical purposes we only report clusters
at a corrected cluster p level (0.05).
Multiple regression analyses were also performed for the pa-
tient group, testing for a possible relationship between FA and
ADC values and each vascular risk factor.
For the FA and ADC correlation analyses, we set the thresh-
old at an uncorrected voxel p value of 0.001.
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Neuropsychological differences between groups were com-
pared using SPSS WIN (version 14.0). Because of the sample
size, the nonparametric Mann–Whitney U test was used for
quantitative variable analyses.
RESULTS Clinical and demographic characteristics.
The sample comprised a patient group of 11 women
and 8 men with a mean age of 61.26 (SD  7.19)
years and mean years of education of 10.37 (SD 
3.55), and a control group with 11 women and 8
men with a mean age of 59.63 (SD  5.37) years
and mean years of education of 11.68 (SD  3.59).
Laboratory tests results for the patients were as
follows: mean glucose 117.40 (SD  35.45) mg/dL,
mean HDL cholesterol 48.92 (SD  14.15) mg/dL,
mean TG 169.20 (SD  95.48) mg/dL, mean sys-
tolic/diastolic blood pressure 136.00 (SD  14.15)/
80.16 (SD  9.66) mm Hg, and mean waist
circumference measure 105.82 (SD  8.78) cm. In
the control group, laboratory test results were as fol-
lows: mean glucose 86.05 (SD  8.36) mg/dL, mean
HDL cholesterol 69.05 (SD0 13.61) mg/dL, mean
TG 78.05 (SD  24.54) mg/dL, mean systolic/
diastolic blood pressure 121.21 (SD  8.41)/75.05
(SD  5.90) mm Hg, and mean waist circumference
measure 84.71 (SD  8.54) cm.
There was no difference between the groups in
age, years of education, or sex. All the patients ful-
filled the criteria for diagnosis of metabolic syn-
drome. Of our patients, 47.4% had 3 vascular risk
factors of metabolic syndrome, 26.3% had 4 factors,
and 26.3% had 5.
The most prevalent vascular risk factor among pa-
tients was central obesity (100%), followed by hyper-
tension (78.94%), low levels of HDL cholesterol
(73.68%), fasting glucose (73.68%), and hypertri-
glyceridemia (57.89%).
Patients and controls did not present statistical
differences in cognitive performance (table e-2).
FA results. The results obtained in the t test for the
contrast of patients  controls showed significant
differences in FA in the frontal lobe bilaterally (table 1
and figure A). No significant results were found in the
reverse contrast.
The correlation analysis of each vascular risk fac-
tor with FA did not show any results at a p level 
0.001 uncorrected.
ADC results. The results for the contrast of pa-
tients  controls in the t test analysis of ADC images
are summarized in table 2 and figure B. Patients with
metabolic syndrome showed higher ADC values in
WM of temporal and frontal lobes bilaterally. No
significant results were found in the reverse contrast.
The correlation analysis of each vascular risk fac-
tor with ADC did not show any results at a p level 
0.001 uncorrected.
DISCUSSION The DTI results indicated that meta-
bolic syndrome involves an alteration in brain micro-
structure. The pattern of damage observed in our
sample showed an anterior–posterior gradient of de-
crease in FA, that is, a greater deterioration of frontal
lobe structures. This FA pattern has been described
in human aging15 and confirmed in animal models.16
In fact, age-sensitive regions of the neocortex are later
areas in terms of phylogenetic evolution and tend to
be the last to mature during brain development.17
It remains unclear how metabolic syndrome af-
fects the brain. Recent findings showed an inverse
association of cardiovascular risk and structural in-
tegrity18 and glucose metabolism19 of the frontal
lobe. Studies of isolated vascular risk factors also re-
ported brain abnormalities, specifically in the frontal
lobe.20–22 The pathophysiologic mechanisms under-
lying these changes are still not clear. The mecha-
nisms currently proposed are increased action of free
radicals, reduction of insulin transport into the brain,
inflammatory activity, and neurotrophic factor
changes.20,22–24
Histopathologic studies have related microvessel
alteration in frontal WM with peripheral atheroscle-






Lobe Size, mm3 x y z t FA Cont FA SdMet r
R ant c callosum F 0.001 5,195 11 25 17 4.51 0.33 0.28 0.60
R ant c callosum F 17 45 16 4.00 0.33 0.28 0.55
R uncinate fas F 29 27 2 3.81 0.35 0.32 0.54
L ant c callosum F 0.043 2,886 10 26 18 4.37 0.32 0.27 0.59
L uncinate fas Sub 27 19 9 4.34 0.34 0.30 0.59
L ant c callosum Lb 10 34 9 3.59 0.32 0.29 0.51
FA  fractional anisotropy; MNI  Montreal Neurological Institute; corr  corrected; Size  cluster size; t  Student t test
values; FA Cont  FA mean values in the control group; FA SdMet  FA mean values in the patient group; r  effect size;
ant  anterior; c  corpus; F  frontal lobe; fas  fasciculus; Sub  sublobar; Lb  limbic lobe.
440 Neurology 73 August 11, 2009
rosis and aging.25 WM alterations correspond to ax-
onal loss and gliosis processes.26 An animal model of
ischemia showed that chronic hypoperfusion in the
brain induces glial changes, especially in anterior
brain regions.27 The processes reported above were
proposed as the pathologic mechanisms underlying the
WM changes seen in FA and ADC in aging and cere-
brovascular disease.12,28 In a study of symptomatic and
asymptomatic cerebrovascular disease patients, the FA
decrease and the mean diffusivity increase correlated
with changes in the N-acetylaspartate neuronal marker
relating the axonal loss/dysfunction to the changes in
DTI measures.29
The disturbances associated with the syndrome pro-
mote pathologic changes in arteries.4 In fact, patients
with metabolic syndrome have a higher risk of stroke,30
reflecting the influence of the syndrome in altering
brain-supplying large arteries. However, the syndrome
is also associated with intracranial atherosclerosis,31
which may be the cause of small-vessel disease. In turn,
small-vessel disease could be responsible for microstruc-
ture alteration, due to a chronic state of vascular dereg-
ulation in the brain mostly affecting the WM.
There is a growing interest in the study of the early
phases of microangiopathies. These diseases are fre-
quent in the elderly and constitute an independent risk
factor for recurrent vascular events and cognitive im-
pairment.32 Therefore, the detection and follow-up of
prodromal states of pathology could elucidate the rele-
vant factors that influence the progression of the disease
and provide useful information for developing preven-
tion programs.
Figure Fractional anisotropy and apparent diffusion coefficient differences between groups
The selected image illustrates the significant regions where patients showed a decrease in fractional anisotropy values
compared with controls (A) and an increase in apparent diffusion coefficient values with respect to controls (B). The color
bar represents t scores. Statistical Parametric Maps (SPMs) are represented according to neurologic convention (left
corresponding to the left hemisphere) and are displayed superimposed on an SPM brain template.
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Metabolic syndrome is a cluster of vascular risk
factors that is frequently concomitant with other pa-
thologies such as coronary artery disease, peripheral
arterial disease and stroke, chronic kidney disease,
nonalcoholic fatty liver disease,e8 polycystic ovary
syndrome,e9 and obstructive sleep apnea.e10 We
sought to avoid these pathologies through our sam-
ple selection and thus be able to identify the initial
effect of the syndrome on the adult brain in isolation
from other influences. We matched groups by age
and applied strict exclusion criteria to avoid the pos-
sible confounding effects of other diseases. At the
same time, these criteria reduced the number of sub-
jects included in the sample and limited the number
of subjects with 4 or 5 metabolic syndrome vascular
risk factors who are usually excluded because of their
cardiovascular complications; therefore, almost half
of our sample comprised persons with 3 factors, the
minimum required to fulfill the syndrome diagnosis.
Another limitation is the fact that the control
sample comprised people without any vascular risk
factors. These criteria enabled us to ensure a healthy
control group but, at the same time, made it impos-
sible to compare people without vascular risk factors,
people with 1 or 2 factors, and patients with meta-
bolic syndrome. Moreover, the patients were not ho-
mogeneous in relation to the specific vascular risk
factor suffered, even though all of them fulfilled the cri-
teria for metabolic syndrome diagnosis (according to
the established definition1). In fact, these 2 limitations
meant that we could not study the synergic effects of the
vascular risk factors in our sample.33 These limitations
need to be resolved in future studies.
Previous studies have linked some isolated vascu-
lar risk factors of the syndrome with WM damage,
such as hypertension,34 obesity,35 and type 2 diabe-
tes.36 However, in our study the correlation analysis
did not show significant results. These negative re-
sults could be due to the small sample size and the
resulting lack of statistical power.
Among the vascular risk factors of the syndrome,
hypertension seems to be the one most closely associ-
ated with WM abnormalities.29,34 The lack of a sig-
nificant correlation in our study could be due to the
effects of antihypertensive drugs. This is an impor-
tant issue in the study of aging,37 because antihyper-
tensive drugs reduce the risk of dementia38 and
reduce the neuropathologic changes in Alzheimer
disease.39 In fact, earlier studies found only a moder-
ate risk of WM damage in controlled hypertensive
patients compared with normotensive controls, and a
higher risk in poorly controlled hypertensive pa-
tients.40 In view of these findings, and because all
patients in our study who had this risk factor were
moderately hypertensive and receiving treatment,
our results may in fact have been influenced by the
effect of medication.
Follow-up studies of these patients might show
how the profile of brain damage evolves and also help
to define any possible cognitive impairment derived
from WM deterioration in these patients. At all
events, the control of metabolic syndrome and its
evolution should be a principal target of study in
societies in which there is a progressive increase in its
prevalence and an increasingly aging population.





Lobe Size, mm3 x y z t ADC* Cont ADC* SdMet r
L inf longitudinal fas T 0.000 22,673 54 28 14 4.31 79.48 86.39 0.58
L inf longitudinal fas T 43 8 29 4.22 81.13 88.61 0.58
L inf longitudinal fas T 36 1 38 4.20 82.27 87.09 0.57
R inf longitudinal fas T 0.009 4,732 44 25 7 4.12 85.07 90.79 0.57
R inf longitudinal fas T 49 34 6 3.86 81.90 87.60 0.54
R inf longitudinal fas T 46 21 32 3.41 82.27 93.94 0.47
L ant c callosum F 0.013 4,480 18 14 40 3.99 74.88 80.29 0.55
L ant c callosum Lb 8 13 44 3.21 92.51 102.25 0.47
L sup longitudinal fas F 37 3 20 3.19 77.24 81.54 0.47
R ant c callosum F 0.013 4,452 17 51 17 4.61 89.64 107.51 0.61
R ant c callosum F 14 36 22 4.11 95.15 110.86 0.57
R ant c callosum F 9 40 35 2.91 94.57 116.83 0.44
*Apparent diffusion coefficient (ADC) values (mm2/s  106).
MNI  Montreal Neurological Institute; corr  corrected; Size  cluster size; t  Student t test values; ADC Cont  ADC
mean values in the control group; ADC SdMet  ADC mean values in the patient group; r  effect size; inf  inferior; fas 
fasciculus; T  temporal lobe; ant  anterior; c  corpus; F  frontal lobe; sup  superior; Lb  limbic lobe.
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level of evidence, the final level will be adjudicated by an independent team prior to publication. Ultimately, these levels can be
translated into classes of recommendations for clinical care, as shown below (right). For more information, please access the
articles and the editorial on the use of classification of levels of evidence published in Neurology.1-3
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